Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled SAD/MAD study of oral LYC-30937 in healthy men
NL-OMON41886Phase 1Active, not recruiting
- Sponsor
- Lycera
- Start
- Apr 2015
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune colitis and inflammatory bowel disease (IBD) comparing LYC-30937 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetic parameters and 1 more. Started Apr 2015; status: active, not recruiting.
02
Drugs
parimifasor
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON41886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41886.